Merck & Co Inc (MRK)

64.18
0.40 0.63
NYSE : Health Care
Prev Close 63.78
Open 63.70
Day Low/High 63.57 / 64.44
52 Wk Low/High 54.63 / 66.80
Volume 2.96M
Avg Volume 9.07M
Exchange NYSE
Shares Outstanding 2.74B
Market Cap 174.75B
EPS 1.40
P/E Ratio 40.69
Div & Yield 1.88 (2.90%)

Latest News

100 Healthy Years - Are Kids Prepared?

100 Healthy Years - Are Kids Prepared?

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street Makes a Comeback as Walmart Distracts From Trump Troubles

Wall Street snaps back to gains on Thursday as positive earnings from Walmart help distract from brewing trouble in Washington, D.C.

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

FDA Approves Merck's KEYTRUDA® (pembrolizumab) For Certain Patients With Locally Advanced Or Metastatic Urothelial Carcinoma, A Type Of Bladder Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.

Cramer: Let Loose the Growth Hounds

Cramer: Let Loose the Growth Hounds

Day 2 of the selloff brings in an entirely new kind of buyer.

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks Add to Gains as Walmart, Health Care Drive Market Comeback

Stocks add to gains on Thursday, coming back from their worst losses in eight months a day earlier, as a positive quarter for Walmart boosts consumer names.

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

Incyte Shares Vault After 'IDO' Cancer Immunotherapy Combo Data Revealed

The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks Turn Higher as Walmart, Health Care Overshadow Trump Trouble

Stocks turn higher as Walmart does the heavy lifting on the Dow and S&P 500, and health care gives a boost to the Nasdaq.

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Biotech Movers: Fast Track Designation Sends Sage Shares Higher

Sage Therapeutics, Incyte and Shire were among the biotech movers in premarket trading on Thursday.

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA Edges Full-Year Guidance Higher After Solid Q1 Earnings

Merck KGaA posted slightly stronger-than-expected first quarter earnings Thursday and nudged its full-year profit guidance higher after a key drug approval in the United States.

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend

Merck Keytruda-Chemo ASCO '17 Update Shows Lung Cancer Survival Trend

The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.

Data For KEYTRUDA® (pembrolizumab) Across 16 Types Of Cancer From Merck's Industry-Leading Immuno-Oncology Program To Be Presented At The 2017 ASCO Annual Meeting

Data For KEYTRUDA® (pembrolizumab) Across 16 Types Of Cancer From Merck's Industry-Leading Immuno-Oncology Program To Be Presented At The 2017 ASCO Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new and updated data from studies of KEYTRUDA ® (pembrolizumab), the company's anti-PD-1 therapy, will be presented at the 53 rd...

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech, Merck Team on Cancer Drug Trial

Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Jim Cramer -- Citi's Downgrade of Pfizer Not Totally Reasonable

Citigroup had a 'thoughtful' research piece on Pfizer, but downgrading it partly based on 'transaction risk' seems unreasonable, Cramer said.

Merck To Present New Phase 3 Data On Investigational Ertugliflozin, Additional Analyses Of Studies Of JANUVIA® (sitagliptin), And Real-World Evidence Research At The 77th Scientific Sessions Of The American Diabetes Association

Merck To Present New Phase 3 Data On Investigational Ertugliflozin, Additional Analyses Of Studies Of JANUVIA® (sitagliptin), And Real-World Evidence Research At The 77th Scientific Sessions Of The American Diabetes Association

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that 19 scientific presentations from Merck's diabetes pipeline and portfolio - including Phase 3 data for investigational ertugliflozin,...

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street

Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.

Snap, Retailers Sell Off on Earnings Disappointments; Nasdaq on Track to End Record Streak

Snap, Retailers Sell Off on Earnings Disappointments; Nasdaq on Track to End Record Streak

Stocks hold modest losses on Thursday as a selloff in Snap pulls the rest of the tech sector lower, while Macy's leads other retailers lower.

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

Merck Up on Approval, Teva Sinks on Earnings and Asset Sales: Biotech Movers

The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.

Stock Losses Accelerate as Macy's Leads Retailers Lower and Snap Plunges

Stock Losses Accelerate as Macy's Leads Retailers Lower and Snap Plunges

Stock losses accelerate on Thursday as a disappointing quarter from Macy's spooks the rest of the retail sector.

Updates to Our Merck Trade

Making changes on last night's news and this morning's action.

Stock Futures Fall as Snap Tanks on Massive Quarterly Loss

Stock Futures Fall as Snap Tanks on Massive Quarterly Loss

Stock futures move lower on Thursday after Snap disappoints in its first earnings report since going public.

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Merck Extends Immunotherapy Lead With Lung Cancer Combination Therapy Approval

Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Cancer Immunotherapy Fallout From Roche's Bladder Cancer Failure

Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche's Loss In Bladder Cancer Lifts Astrazeneca and Could Boost Bristol-Myers

Roche, the Swiss drugmaker, was let down by Tecentriq in clinical trials providing scope for Astra to close the gap and a possible boost for Bristol on Wednesday

Merck Ready to Resume Long-Term Uptrend

Merck Ready to Resume Long-Term Uptrend

The price momentum and money flow indicators of the drug maker are in positive alignment.

Weekly Roundup: Old Trends Kick Into Gear

Selling premium on big names vs. buying premium has been the superior strategy this earnings season.

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Group Stink; Good, the Bad and the Ugly: Doug Kass' Views

Doug Kass shares his thoughts on Facebook, Allergan and Apple.